Philippine Regional Court Denies Patent Protection For Pfizer Drug
This article was originally published in PharmAsia News
Executive SummaryA Philippine regional court denied U.S.-based Pfizer's attempt to block a United Laboratories launch of a generic version of Caduet (atorvastatin) for treating hypertension
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.